Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

About this update from Vivos Therapeutics, Inc.

LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC (“Streeterville”). Under the extended agreement, Streeterville has extended the timeframe of the arrangement through August 31, 2026 and reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a combination of perpetual, non-convertible preferred stock and shares of common stock of the Company. The extension follows the Company’s determination that the original agreement provided too short a timeframe for Vivos to complete its capital-raising requirements. Why the Agreement Was Extended The original agreement, announced earlier this month, committed Streeterville to converting its debt into equity on a dollar-for-dollar basis with equity raised by the Company. The Company determined that the original timeframe of June 15 was too short to complete its planned equity raise in an organized manner. The extension to August 31, 2026 provides additional time while Streeterville reaffirms its commitment to convert, with the conversion structured entirely into a combination of perpetual, non-convertible preferred stock and shares of common stock. Key Terms of the Extension Management Commentary “We are grateful to Streeterville for their cooperation in agreeing to extend,” said R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics. “The extra time will allow the Company to raise the needed equity in an organized fashion and to allow the announced rights offering to start during that timeframe. We believe the Company has successfully pivoted over to its new strategic business model and is performing well on the new strategy. The spirit of cooperation and support from Streeterville has been particularly helpful.” About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffer...

View stock analysis, news, and events for Vivos Therapeutics, Inc.